-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
January 2021
-
A New Year’s Resolution to Promote the Use of Patient-Sensitive Language
In 2021, people living with lung cancer and their caregivers will likely be attending virtual oncology conferences such as the 2020 WCLC and making deep dives into research in record numbers. Due to improvements in lung cancer diagnosis and treatment, more patients with lung cancer are living longer and better, thus becoming increasingly involved in…
-
WCLC Conference Chairs Offer Insights on The New All-Virtual Program, The Year Ahead
The Chairs of the 2020 World Conference on Lung Cancer, all based in Asia, had originally designed a live program to be hosted in Singapore. The outbreak of COVID-19 forced Drs. Yi-Long Wu, Ross Soo, and Daniel Tan to not only reschedule the live event to a virtual program but to also re-imagine the program.…
-
2020 Adi F. Gazdar IASLC Merit Award Recipient: Dr. Alex A. Adjei
Alex A. Adjei, MD, PhD, is a Professor of Oncology and Professor of Pharmacology in the Mayo College of Medicine. He has had a passion for drug development in cancer, as well as for mentoring the next generation of specialists during his multifaceted career. For his many accomplishments in cancer drug development, Dr. Adjei has…
-
Role of Thai Oncology Pharmacists in Lung Cancer Treatment: A Q&A With Dr. Suthan Chanthawong
Suthan Chanthawong, BPharm, BCP, BCOP, is an assistant professor of Pharmaceutical Sciences in the Division of Clinical Pharmacy at Khon Kaen University, in Thailand. In the following interview, he discusses how oncology pharmacists differ from other pharmacists in his region, as well as the role they play in supporting decision making to balance the cost…
-
PD-L1 Blockade Reinvigorates Dendritic Cells for Antitumor Immunity
In reference to: Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12(534):eaav7431. Checkpoint blockade with PD-1 or PD-L1 inhibitors has shown durable clinical responses across many cancer types. Previously, it had been generally believed that PD-1/PD-L1 blockade generates antitumor immunity by reinvigorating the…
-
Research’s Race to Stop a Pandemic
Experts discuss how a global pandemic is putting pressure on traditional methods of research dissemination. A search on PubMed.gov for COVID-19 reveals 93,851 results as of Mid-January 2021. “To put that in perspective, if I search for EGFR, a major area of cancer research, there are just over 96,000 results in the 40 years since…
-
Should We Delay Lung Cancer Screening During the COVID-19 Pandemic?
To address the issue of low-dose CT screening, during the COVID-19 pandemic, for lung cancer and management of both screen-detected nodules and incidentally detected nodules, various eminent organizations and expert groups have created guidance documents.1-4 The overarching principal guiding safe resumption of nonurgent imaging is clearly stated in a separate document by the American College…
-
Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey
The past 10 years have seen a dramatic increase in novel therapeutic options for patients with lung cancer, with many treatments now personalized to the specific tumor characteristics of each patient’s disease.1,2 The majority of these novel therapies are either immunotherapies or molecularly targeted agents. Identification of the best therapeutic option for every patient before…
-
Statistical Design Flexibility Versus Optimism: The Example of KEYNOTE-604
In the era of targeted treatments and immunotherapies, it is relatively common to address multiple questions in a single phase III clinical trial. These questions often involve using more than one primary endpoint (either co-primary or hierarchically tested), planning a number of interim analyses, and testing more than one experimental treatment and/or cohorts from different…
-
Impactful Multidisciplinary Care Not Out of Reach in Community Settings
In 2014 the IASLC, in collaboration with the American Thoracic Society and the European Respiratory Society, published a new classification of lung adenocarcinoma.1 The publication addressed new terminology and diagnostic criteria for lung adenocarcinoma, but it also highlighted “the importance of a close collaboration between oncologist, pathologist, molecular biologist, radiologist and surgeons … to offer…
View ILCN Archives
Provider Resources
Popular Articles